On March 29, 2017 Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, reported that new preclinical data on tazemetostat, Epizyme’s lead product candidate and first-in-class EZH2 inhibitor, along with other epigenetic target identification efforts, will be presented in poster sessions at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2017 taking place in Washington, D.C., April 1-5, 2017 (Press release, Epizyme, MAR 29, 2017, View Source [SID1234518311]). Schedule your 30 min Free 1stOncology Demo! "2017 continues to be a transformational year for Epizyme as we work to rewrite cancer treatment through novel epigenetic medicines," said Rob Bazemore, CEO of Epizyme. "We look forward to sharing these new data on tazemetostat and our innovative approach to advancing our preclinical pipeline with the oncology community at AACR (Free AACR Whitepaper)."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As we evaluate these data, we are particularly encouraged by new research revealing the important role EZH2 plays in the proliferation of multiple myeloma, and preclinical activity of our first-in-class EZH2 inhibitor, tazemetostat, as both monotherapy and combination therapy in in vitro models of multiple myeloma," said Richard Chesworth, DPhil, senior vice president of research at Epizyme. "These findings reinforce the potential for tazemetostat as a treatment option across multiple B-cell malignancies."
Multiple myeloma is a cancer arising from terminally differentiated B-cell lymphocyte plasmablasts. Mounting evidence suggests that EZH2 is an important regulator of B-cell differentiation and may play an important role in clinical B-cell malignancies. Consistent with this role, inhibition of EZH2 alone has shown potent anti-proliferative effects in in vitro and in vivo preclinical models of multiple myeloma.
In a new study being presented at AACR (Free AACR Whitepaper), Epizyme evaluated the efficacy of tazemetostat, an EZH2 inhibitor, as monotherapy and in combination with standard of care agents in preclinical models of multiple myeloma. Tazemetostat selectively inhibited intracellular H3K27 methylation in multiple myeloma cell lines and elicited a robust anti-proliferative effect in 14-day assays. Synergistic activity was observed when tazemetostat was combined with commonly used multiple myeloma therapeutics (glucocorticoid receptor agonists and small molecule immune system modulators) when cells were treated with tazemetostat for seven days prior to the addition of the standard-of-care drugs. Based on these results, studies with selected therapeutic modalities were expanded into in vivo xenograft models to further evaluate monotherapy and combination activity of tazemetostat in multiple myeloma.
Data will also be presented from preclinical studies demonstrating synergistic activity following the addition of tazemetostat to current small molecule treatments for malignant rhabdoid tumors and atypical teratoid rhabdoid tumors, both rare and aggressive forms of cancer with high unmet medical need, typically affecting pediatric patients. In addition, Epizyme will present data demonstrating that tazemetostat induces potent and selective apoptosis in SMARCA2 and SMARCA4-deficient ovarian cell lines, which confirms SCCOHT (small cell carcinoma of the ovary hypercalcemic type) is also sensitive to CRISPR-mediated EZH2 gene ablation. These findings support Epizyme’s ongoing Phase 2 trial of tazemetostat in solid tumors, and may support future clinical evaluation in other tumor types such as lung cancers.
Details of the poster presentations are as follows:
Date & Time: Sunday, April 2, 1:00 – 5:00 p.m. ET
Title: CRISPR pooled screening of hundreds of cancer cell lines identifies differential dependencies on epigenetic pathways and synthetic lethal relationships
Abstract Number: 406/6
Location: Section 17
Date & Time: Monday, April 3, 8:00 a.m. – 12:00 p.m. ET
Title: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT
Abstract Number: 1944/16
Location: Section 42
Date & Time: Tuesday, April 4, 8:00 a.m. – 12:00 p.m. ET
Title: Selective killing of SMARCA2- and SMARCA4-deficient tumors by inhibition of EZH2: In vitro and in vivo preclinical models
Abstract Number: 3345/6
Location: Section 15
Date & Time: Wednesday, April 5, 8:00 a.m. – 12:00 p.m. ET
Title: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
Abstract Number: 5060/5
Location: Section 2